SCHEMBL24257507

SCHEMBL24257507

Cc1c(-c2cnc(-c3ccccc3)s2)cnc(C#N)c1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.40
KDM4E B2RXH2 7/20 0.40
NPC1 O15118 7/20 0.40
RAB9A P51151 7/20 0.40
LMNA P02545 4/20 0.40
HPGD P15428 4/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
MAPT P10636 3/20 0.40
TDP1 Q9NUW8 2/20 0.40
NFKB1 P19838 3/20 0.39
NFKB2 Q00653 3/20 0.39
RELA Q04206 3/20 0.39
HPGDS O60760 2/20 0.39
S1PR1 P21453 1/20 0.36
S1PR5 Q9H228 1/20 0.36
POLB P06746 1/20 0.35
NPSR1 Q6W5P4 4/20 0.35
CYP1A2 P05177 2/20 0.34
CYP2C9 P11712 2/20 0.34
CYP2C19 P33261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24257734 0.85 PTPN1 (0.41) ALDH1A1KDM4ENPC1RAB9ALMNA
SCHEMBL24257773 0.74 BTK (0.44) ALDH1A1HPGDSMN1; SMN2TDP1POLB
SCHEMBL24257813 0.72 ALOX15 (0.47) ALDH1A1KDM4ENPC1RAB9ALMNA
SCHEMBL24257695 0.72 KDM4E (0.45) ALDH1A1KDM4EHPGDSMN1; SMN2CYP1A2
SCHEMBL30454648 0.72 DHFR (0.44) ALDH1A1KDM4ENPC1RAB9ALMNA
SCHEMBL30453176 0.72 KDM4E (0.45) ALDH1A1KDM4EHPGDSMN1; SMN2CYP1A2
SCHEMBL24257731 0.72 LRRK2 (0.42) ALDH1A1KDM4ENPC1RAB9ALMNA
SCHEMBL24257698 0.72 DHFR (0.44) ALDH1A1KDM4ENPC1RAB9ALMNA
SCHEMBL24257776 0.72 KDM4E (0.41) ALDH1A1KDM4ENPC1RAB9ALMNA
SCHEMBL30453060 0.72 KDM4E (0.41) ALDH1A1KDM4ENPC1RAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
EP-4196466-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE Akebia Therapeutics Inc. (US) 2023-06-21 EP disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 ALDH1A1 1362/4885KDM4E 175/4885NPC1 4011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.